{
  "drug_name": "chlorobutanol",
  "nbk_id": "NBK551556",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK551556/",
  "scraped_at": "2026-01-11T15:26:04",
  "sections": {
    "indications": "Contraindications to procaine include hypersensitivity to procaine or other ester group local anesthetics, PABA, metabolic derivatives of PABA, or to other components of the pharmaceutical suspension. Spinal anesthesia with procaine is contraindicated in cases of septicemia and cerebrospinal diseases such as syphilis and meningitis. Currently, no evidence suggests that procaine is carcinogenic, mutagenic, or gonadotoxic.\n[12]\nPer the FDA, the medication has a Pregnancy Category C rating - therefore, its capacity to cause fetal compromise remains not yet fully established.\n[13]\nIdeally, procaine should only be given to pregnant women only if the benefit of analgesia and subsequent intervention outweighs the risks. Like with other local anesthetics, procaine administration should be undertaken cautiously in patients with cardiac arrhythmias, asthma, sulfite sensitivity, local/systemic infection, and advanced age or debility.\n[14]",
    "mechanism": "Procaine belongs to a class of analgesic medications known as local anesthetics. All local anesthetics consist of three constituents: a lipophilic aromatic ring, a terminal amine, and an intermediate ester or amide group. The aromatic ring serves to improve the anesthetic's lipid solubility and promote diffusion through epineural and neural membranes, thus correlating to the anesthetic's potency.\n[5]\nThe terminal amine may be configured in a lipid-soluble tertiary form or as a water-soluble quaternary form and imparts the anesthetic with binary active/inactive states.\n[5]\nFinally, the intermediate linkage determines the manner of metabolism and classification, either as an aminoamide (amino group) or aminoester (ester group) local anesthetic. Aminoamides undergo hepatic metabolism, whereas aminoesters are hydrolyzed intravascularly by plasma butyrylcholinesterase into para-aminobenzoic acid (PABA). Procaine belongs to the aminoesters, along with tetracaine, cocaine, benzocaine. Aminoamides include bupivacaine, lidocaine, ropivacaine, and mepivacaine. The primary characteristics and clinical correlates of local anesthetics are\n[5]\n:\n\nLipid solubility: Potency\nDissociation constant: Onset\nIntermediate linkage: Metabolism\nPlasma-protein binding affinity: Duration\n\nThe fundamental mechanism of analgesia underlying all local anesthetics is the blockade of neurotransmission via inhibition of sodium channels along nerve fibers. The progression of anesthesia, referred to as differential blockage, is predicated on nerve caliber and myelination and generally blocks nerve fibers in the following order from first to last\n[6]\n:\n\nType B fibers (sympathetic tone)\nType C (dull pain, warm temperature)\nType A-delta (sharp pain, cold temperature)\nType A-gamma (proprioception)\nType A-beta (touch, pressure)\nType A-alpha (motor)\n\nAfter epineural and neural diffusion, procaine reversibly and preferentially binds to active sites on the cytoplasmic aspect of neuronal voltage-gated sodium channels. This binding occurs preferentially during activated states and causes selective inhibition of the open configuration of the sodium channel, thereby preventing sodium influx. The interruption of this influx prevents depolarization needed to initiate and propagate action potentials along the nerve fiber resulting in suppression of neurotransmission of nerve fibers mentioned above, with type C and A-delta fiber suppression mediating the primarily desired analgesic effects of procaine.\n[7]",
    "administration": "In the United States to date, the Food and Drug Administration (FDA) has approved several formulations of procaine in the form of procaine hydrochloride at 1%, 2%, and 10% concentrations. Dilution and addition of epinephrine may be undertaken depending on the procedure performed. A full discussion of such is beyond the scope of this review. Briefly, for infiltrative administration, 0.25% and 0.5% solutions are generally appropriate with a target single-dose total of up to 350 to 600 mg. Pediatric patients may receive a 0.5% solution for local infiltration with a maximum dose of up to 15 mg/kg. For peripheral nerve blocks, procaine solutions of 0.5%, 1%, and 2%Â  are generally appropriate up to 200 mL, 100 mL, and 50 mL, respectively. For neuraxial anesthesia, the 10% solution is usually the choice with total single doses ranging from 50 to 200 mg, depending on the extent of desired anesthesia with an injection rate of 1mL/5 seconds. For local and regional blockade, epinephrine may be supplemented to induce local vasoconstriction and prolong the duration of action at the local site of injection. Single administration dose should never exceed 100 0mg procaine hydrochloride. Patients with cardiac, renal, and hepatic disease and patients who are elderly or acutely ill should receive reduced doses.",
    "adverse_effects": "The adverse effects of procaine administration are similar to those of other aminoester anesthetics. Increased intravascular levels mediate most side effects; this can be due to overdosage, entry into intravascular spaces, and potentiation from reduced metabolism. More rarely, patients may experience adverse effects secondary to hypersensitivity or idiosyncrasy.\n\nHypersensitivity may develop in patients either due to procaine or constituent components in the therapeutic suspension such as sulfites (local vasoconstriction) or chlorobutanol (antimicrobial preservative) with aminoesters more likely to induce hypersensitivity than aminoamides.\n[5]\nThe derivation of procaine from PABA may also result in cross-sensitivity to PABA and its derivatives, as well. Patients often present with anaphylactoid-like symptomatology, including urticaria, pruritus, erythema, laryngeal edema, tachycardia, nausea, vomiting, dizziness, syncope, perspiration, and hyperthermia. Treatment includes cessation of procaine and a tailored regimen of intramuscular epinephrine, supplemental oxygen, intravenous corticosteroids, resuscitative fluids, beta-agonists, and supportive care.\n\nSystemic presence of procaine at supratherapeutic levels results in the compromise of multiple organ systems in a dose-dependent manner known as local anesthetic systemic toxicity (LAST). Procaine, like other anesthetics, binds to beta-adrenergic receptors in addition to voltage-gated sodium channels to mediate cardiotoxic and neurotoxic effects.\n[8]\nCardiac symptoms include heart block, arrhythmia, hemodynamic instability, heart failure, and cardiac arrest.\n[8]\n[9]\nDepression of the central nervous system depression may result in varying presentations of tinnitus, blurred vision, dizziness, akathisia, anxiety, tremors, seizures, coma, unconsciousness, and respiratory arrest.\n[5]\n[9]\nManagement and treatment of procaine-induced LAST include airway management (ventilation, oxygenation), circulatory support (e.g., epinephrine, rhythm control), seizure prophylaxis, and suppression (benzodiazepines, succinylcholine), and reduction of intravascular anesthetic levels (lipid-emulsion, cardiopulmonary bypass).\n[9]\n[10]\n[11]",
    "monitoring": "Following the administration of procaine, signs of local and systemic toxicity or hypersensitivity require monitoring.\n[9]\nMoreover, clinicians should note changes to vital signs and the patient's mental status during and after injection. According to the American Society of Anesthesiology, all patients receiving regional or neuraxial anesthetics require monitoring for\n[15]\n:\n\nElectrocardiography (EKG)\nPulse oximetry\nBlood pressure\n\nThe presence of toxicity, hypersensitivity, or concerning findings from monitoring warrants cessation of the medication and undertaking steps to mitigate and/or reverse symptoms.\n[16]"
  }
}